Telomir Pharmaceuticals, Inc.
TELONasdaqHealthcare · Pharmaceutical Preparations · FL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | −$10.4M | −$16.5M | −$13.1M | −$854,147 |
| Total assets | $7.3M | $1.3M | $4.8M | $48,730 |
| Total liabilities | $1.4M | $680,968 | $1.3M | $986,008 |
| Equity | $5.9M | $643,037 | $3.4M | −$937,278 |
| EPS (diluted) | $-0.33 | $-0.56 | $0.48 | $-0.03 |
| Shares out. | 29.8M | 29.6M | 28.6M | 26.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −176.1%
- Return on assets
- −141.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 19.5%
- Debt / equity
- 0.24×
- Book value / share
- $0.20
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −91.6%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Dejoria John PaulPassive (13G)Feb 12, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.0M | 10.3 | +1.8% |
| Apr 30, 2026 | 1.0M | 3.1 | -1.6% |
| Apr 15, 2026 | 1.0M | 13.7 | -15.1% |
| Mar 31, 2026 | 1.2M | 14.7 | -4.2% |
| Mar 13, 2026 | 1.3M | 16.2 | -11.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 20, 2026
- Other material eventApr 30, 2026
- Entered a material agreement · Completed an acquisition or disposition · Unregistered equity saleApr 24, 2026
- Other material eventMar 31, 2026
- Other material eventMar 31, 2026
- Director / officer change · Amended charter or bylaws · Shareholder voteMar 27, 2026
- Other material eventFeb 17, 2026
- Other material eventFeb 5, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.